Title | Association of Rare Protein-Truncating DNA Variants in APOB or PCSK9 With Low-density Lipoprotein Cholesterol Level and Risk of Coronary Heart Disease. |
Publication Type | Journal Article |
Year of Publication | 2023 |
Authors | Dron, JS, Patel, AP, Zhang, Y, Jurgens, SJ, Maamari, DJ, Wang, M, Boerwinkle, E, Morrison, AC, de Vries, PS, Fornage, M, Hou, L, Lloyd-Jones, DM, Psaty, BM, Tracy, RP, Bis, JC, Vasan, RS, Levy, D, Heard-Costa, N, Rich, SS, Guo, X, Taylor, KD, Gibbs, RA, Rotter, JI, Willer, CJ, Oelsner, EC, Moran, AE, Peloso, GM, Natarajan, P, Khera, AV |
Journal | JAMA Cardiol |
Volume | 8 |
Issue | 3 |
Pagination | 258-267 |
Date Published | 2023 Mar 01 |
ISSN | 2380-6591 |
Keywords | Adult, Aged, Apolipoproteins B, Cholesterol, LDL, Coronary Disease, DNA, Female, Humans, Male, Middle Aged, Proprotein Convertase 9, Prospective Studies |
Abstract | IMPORTANCE: Protein-truncating variants (PTVs) in apolipoprotein B (APOB) and proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with significantly lower low-density lipoprotein (LDL) cholesterol concentrations. The association of these PTVs with coronary heart disease (CHD) warrants further characterization in large, multiracial prospective cohort studies. OBJECTIVE: To evaluate the association of PTVs in APOB and PCSK9 with LDL cholesterol concentrations and CHD risk. DESIGN, SETTING, AND PARTICIPANTS: This studied included participants from 5 National Heart, Lung, and Blood Institute (NHLBI) studies and the UK Biobank. NHLBI study participants aged 5 to 84 years were recruited between 1971 and 2002 across the US and underwent whole-genome sequencing. UK Biobank participants aged 40 to 69 years were recruited between 2006 and 2010 in the UK and underwent whole-exome sequencing. Data were analyzed from June 2021 to October 2022. EXPOSURES: PTVs in APOB and PCSK9. MAIN OUTCOMES AND MEASURES: Estimated untreated LDL cholesterol levels and CHD. RESULTS: Among 19 073 NHLBI participants (10 598 [55.6%] female; mean [SD] age, 52 [17] years), 139 (0.7%) carried an APOB or PCSK9 PTV, which was associated with 49 mg/dL (95% CI, 43-56) lower estimated untreated LDL cholesterol level. Over a median (IQR) follow-up of 21.5 (13.9-29.4) years, incident CHD was observed in 12 of 139 carriers (8.6%) vs 3029 of 18 934 noncarriers (16.0%), corresponding to an adjusted hazard ratio of 0.51 (95% CI, 0.28-0.89; P = .02). Among 190 464 UK Biobank participants (104 831 [55.0%] female; mean [SD] age, 57 [8] years), 662 (0.4%) carried a PTV, which was associated with 45 mg/dL (95% CI, 42-47) lower estimated untreated LDL cholesterol level. Estimated CHD risk by age 75 years was 3.7% (95% CI, 2.0-5.3) in carriers vs 7.0% (95% CI, 6.9-7.2) in noncarriers, corresponding to an adjusted hazard ratio of 0.51 (95% CI, 0.32-0.81; P = .004). CONCLUSIONS AND RELEVANCE: Among 209 537 individuals in this study, 0.4% carried an APOB or PCSK9 PTV that was associated with less exposure to LDL cholesterol and a 49% lower risk of CHD. |
DOI | 10.1001/jamacardio.2022.5271 |
Alternate Journal | JAMA Cardiol |
PubMed ID | 36723951 |
PubMed Central ID | PMC9996405 |
Grant List | R01 HL105756 / HL / NHLBI NIH HHS / United States 75N92022D00001 / HL / NHLBI NIH HHS / United States 75N92022D00002 / HL / NHLBI NIH HHS / United States 75N92022D00003 / HL / NHLBI NIH HHS / United States 75N92022D00004 / HL / NHLBI NIH HHS / United States 75N92022D00005 / HL / NHLBI NIH HHS / United States HHSN268201800005I / HL / NHLBI NIH HHS / United States HHSN268201800007I / HL / NHLBI NIH HHS / United States HHSN268201800003I / HL / NHLBI NIH HHS / United States HHSN268201800006I / HL / NHLBI NIH HHS / United States HHSN268201800004I / HL / NHLBI NIH HHS / United States HHSN268201200036C / HL / NHLBI NIH HHS / United States HHSN268200800007C / HL / NHLBI NIH HHS / United States HHSN268201800001C / HL / NHLBI NIH HHS / United States N01HC55222 / HL / NHLBI NIH HHS / United States N01HC85079 / HL / NHLBI NIH HHS / United States N01HC85080 / HL / NHLBI NIH HHS / United States N01HC85081 / HL / NHLBI NIH HHS / United States N01HC85082 / HL / NHLBI NIH HHS / United States N01HC85083 / HL / NHLBI NIH HHS / United States N01HC85086 / HL / NHLBI NIH HHS / United States 75N92021D00006 / HL / NHLBI NIH HHS / United States U01 HL080295 / HL / NHLBI NIH HHS / United States U01 HL130114 / HL / NHLBI NIH HHS / United States R01 AG023629 / AG / NIA NIH HHS / United States 75N92020D00001 / HL / NHLBI NIH HHS / United States HHSN268201500003I / HL / NHLBI NIH HHS / United States N01 HC095159 / HC / NHLBI NIH HHS / United States N01 HC095160 / HC / NHLBI NIH HHS / United States N01 HC095161 / HC / NHLBI NIH HHS / United States N01 HC095162 / HC / NHLBI NIH HHS / United States N01 HC095163 / HC / NHLBI NIH HHS / United States N01 HC095164 / HC / NHLBI NIH HHS / United States N01 HC095165 / HC / NHLBI NIH HHS / United States N01 HC095166 / HC / NHLBI NIH HHS / United States N01 HC095167 / HC / NHLBI NIH HHS / United States N01 HC095168 / HC / NHLBI NIH HHS / United States N01 HC095169 / HC / NHLBI NIH HHS / United States 75N92020D00005 / HL / NHLBI NIH HHS / United States 75N92020D00002 / HL / NHLBI NIH HHS / United States 75N92020D00003 / HL / NHLBI NIH HHS / United States 75N92020D00006 / HL / NHLBI NIH HHS / United States 75N92020D00004 / HL / NHLBI NIH HHS / United States 75N92020D00007 / HL / NHLBI NIH HHS / United States UL1 TR000040 / TR / NCATS NIH HHS / United States UL1 TR001079 / TR / NCATS NIH HHS / United States UL1 TR001420 / TR / NCATS NIH HHS / United States UL1 TR001881 / TR / NCATS NIH HHS / United States R01 HL105756 / HL / NHLBI NIH HHS / United States N02 HL64278 / HL / NHLBI NIH HHS / United States R01 HL071051 / HL / NHLBI NIH HHS / United States R01 HL071205 / HL / NHLBI NIH HHS / United States R01 HL071250 / HL / NHLBI NIH HHS / United States R01 HL071251 / HL / NHLBI NIH HHS / United States R01 HL071258 / HL / NHLBI NIH HHS / United States R01 HL071259 / HL / NHLBI NIH HHS / United States UL1 TR001881 / TR / NCATS NIH HHS / United States UL1 RR033176 / RR / NCRR NIH HHS / United States U54 HG003273 / HG / NHGRI NIH HHS / United States HHSN268201500015C / HL / NHLBI NIH HHS / United States R01 HL092577 / HL / NHLBI NIH HHS / United States HHSN268201600031C / HL / NHLBI NIH HHS / United States HHSN268201500015C / HL / NHLBI NIH HHS / United States U54 HG003067 / HG / NHGRI NIH HHS / United States HHSN268201500014C / HL / NHLBI NIH HHS / United States OT3 HL142479 / HL / NHLBI NIH HHS / United States OT3 HL142478 / HL / NHLBI NIH HHS / United States OT3 HL142481 / HL / NHLBI NIH HHS / United States OT3 HL142480 / HL / NHLBI NIH HHS / United States OT3 HL147154 / HL / NHLBI NIH HHS / United States U01 HG011719 / HG / NHGRI NIH HHS / United States R01 HL146860 / HL / NHLBI NIH HHS / United States R01 HL141823 / HL / NHLBI NIH HHS / United States R01 HL142711 / HL / NHLBI NIH HHS / United States R01 HL127564 / HL / NHLBI NIH HHS / United States K08 HG010155 / HG / NHGRI NIH HHS / United States U01 HG011719 / HG / NHGRI NIH HHS / United States |
Association of Rare Protein-Truncating DNA Variants in APOB or PCSK9 With Low-density Lipoprotein Cholesterol Level and Risk of Coronary Heart Disease.
Similar Publications
Deep sequencing of candidate genes identified 14 variants associated with smoking abstinence in an ethnically diverse sample. Sci Rep. 2024;14(1):6385. | .
FAIR Header Reference genome: a TRUSTworthy standard. Brief Bioinform. 2024;25(3). | .
Gut Microbiota and Blood Metabolites Related to Fiber Intake and Type 2 Diabetes. Circ Res. 2024;134(7):842-854. | .